Skip to main navigation Skip to search Skip to main content

Optimising Multi-stakeholder Practices in Patient Engagement: A Gap Analysis to Enable Focused Evolution of Patient Engagement in the Development and Lifecycle Management of Medicines

  • S. D. Faulkner*
  • , C. A.C.M. Pittens
  • , N. S. Goedhart
  • , E. H. Davies
  • , E. Manning
  • , A. Diaz-Ponce
  • , Maria Jose Vicente Edo
  • , L. Prieto-Remón
  • , L. Husain
  • , K. Huberman
  • , M. Boudes
  • , M. Subramaniam
  • *Corresponding author for this work

Research output: Contribution to JournalArticleAcademicpeer-review

Abstract

Background: The PARADIGM consortium aimed to make patient engagement in the development and lifecycle management of medicines easier and more effective for all, with the development of new tools that fulfil robustly defined gaps where engagement is suboptimal.

Aims: To generate an inventory of gaps in patient engagement practices and process from existing global examples.

Methods: A large set of criteria for effective patient engagement previously defined via a multi-stakeholder Delphi method, were mapped under fourteen overarching themes. A gap analysis was then performed by twenty-seven reviewers against the resulting forty-six mapped criteria, on a sample of seventy initiatives from global databases. Results: An inventory of gaps was identified including contextual information as to why the gaps exist. Our work identified general patterns where patient engagement was suboptimal—defined as; fragmented reporting and dissemination of patient engagement activities, and the fundamental principles defined in frameworks or guidance being poorly adhered to in actual practice. Specific gaps were identified for sixteen criteria. Additionally, it was also common to observe primary aspects of a process were addressed for a given criteria (i.e. training for roles and responsibilities) but a secondary context element was lacking (i.e. making training material accessible/understandable/meaningful to all participants).

Conclusion: The results show that the evolution towards meaningful and systematic patient engagement is occurring, yet more importantly they provide clear directional insights to help enhance collaborative practices and co-design solutions. This targeted impact to catalyse a needs-oriented health system that integrates patient engagement at its core is essential.

Original languageEnglish
Pages (from-to)1165-1179
Number of pages15
JournalTherapeutic Innovation and Regulatory Science
Volume55
Issue number6
Early online date28 Jun 2021
DOIs
Publication statusPublished - Nov 2021

Bibliographical note

Publisher Copyright:
© 2021, The Author(s).

Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.

Funding

PARADIGM has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement 777450. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

FundersFunder number
Innovative Medicines Initiative
European Federation of Pharmaceutical Industries and Associations
Horizon 2020 Framework Programme777450

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 16 - Peace, Justice and Strong Institutions
      SDG 16 Peace, Justice and Strong Institutions
    2. SDG 17 - Partnerships for the Goals
      SDG 17 Partnerships for the Goals

    Keywords

    • Gap analysis
    • Medicine research and development
    • Medicines lifecycle
    • Patient engagement
    • Practices
    • Processes

    Fingerprint

    Dive into the research topics of 'Optimising Multi-stakeholder Practices in Patient Engagement: A Gap Analysis to Enable Focused Evolution of Patient Engagement in the Development and Lifecycle Management of Medicines'. Together they form a unique fingerprint.

    Cite this